22.05EUR-2.43%Mkt Cap: 389.69M EURP/E: —Last update: 2026-06-01
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap389.69M EUR
Enterprise Value317.15M EUR
Revenue (TTM)44.48M EUR
Gross Profit3.58M EUR
Net Income (TTM)-64.70M EUR
Revenue/Share2.517 EUR
Last Price22.05 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees203
CountryDE
SectorHealthcare
IndustryBiotechnology
ISINDE000A1EWVY8
Valuation
P/E (Trailing)—
P/E (Forward)20.35
PEG—
EV/EBITDA-65.87
EV/Revenue7.13
P/S8.98
P/B1.00
EPS (TTM)-3.66
EPS (Forward)1.11
52W Range
15.8040% of range31.30
52W High31.30 EUR
52W Low15.80 EUR
Profitability
Gross Margin8.04%
Oper. Margin41.40%
EBITDA Margin-10.83%
Profit Margin-145.46%
ROE-16.21%
ROA-8.75%
Growth
Revenue Growth-12.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF10.78M EUR
CapEx (TTM)54.89M EUR
FCF Margin-68.55%
FCF Yield-7.82%
Net Debt-59.28M EUR
Net Debt/EBITDA12.31
Balance Sheet
Debt/Equity0.02
Current Ratio2.33
Quick Ratio1.89
Book Value/Sh22.59 EUR
Cash/Share3.896 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)39.86 EUR
Target Range30.00 EUR – 53.00 EUR
# Analysts7
Ownership
Shares Out.17.67M
Float13.36M
Insiders30.00%
Institutions31.26%
Technical
SMA 5018.65 (+18.2%)
SMA 20022.03 (+0.1%)
Beta0.65
S&P 52W Chg27.70%
Avg Vol (30d)12.12K
Avg Vol (10d)13.54K
Technical Indicators
RSI (14)69.0
MACD0.6667
MACD Signal0.3151
MACD Hist.+0.3516
BB Upper21.76 EUR
BB Middle19.32 EUR
BB Lower16.87 EUR
BB Width25.36%
ATR (14)1.169 EUR
Vol Ratio (20d)1.78x